4,024 Eli Lilly and Company $LLY Shares Acquired by Mather Group LLC.

Mather Group LLC. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 44.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,156 shares of the company’s stock after buying an additional 4,024 shares during the quarter. Mather Group LLC.’s holdings in Eli Lilly and Company were worth $15,223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $30,000. Maseco LLP raised its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the period. Aventus Investment Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts at Erste Group raised their FY2026 EPS estimate to $36.55 from $36.45 and their FY2027 forecast to $47.30 from $47.18, reinforcing expectations for continued profit growth above consensus. Analyst earnings estimates
• Positive Sentiment: Investor commentary continues to highlight Lilly’s dominant position in diabetes and obesity treatments, strong revenue growth and a pipeline that could support further expansion beyond Zepbound. Retatrutide is viewed as a particularly important future growth opportunity ahead of the company’s October 29 earnings report. Retatrutide earnings outlook
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to test the experimental breast-cancer drug PRT13722 in combination with established therapies. Enrollment is expected to begin in the fourth quarter, adding potential long-term oncology value to Lilly’s pipeline. Prelude and Lilly breast cancer collaboration
• Positive Sentiment: Broader oncology spending is projected to exceed $400 billion globally by 2028, creating an attractive market backdrop for Lilly’s cancer-drug development and partnerships. Cancer drug spending outlook
• Neutral Sentiment: A Phase 1 food-effect study for tersolisib represents incremental pipeline progress, but the early-stage trial is unlikely to materially affect near-term earnings or valuation. Tersolisib study update
• Negative Sentiment: Valuation remains a concern after a roughly 404% five-year rally. Lilly trades at a high earnings multiple, so the stock may need sustained obesity-drug growth and successful pipeline launches to justify its price. Investors also face near-term volatility around the upcoming earnings release and clinical data.
• Negative Sentiment: A combination treatment generated greater weight loss than Zepbound in reported findings, but discontinuation rates were substantially higher, highlighting potential tolerability and adherence challenges for next-generation obesity therapies. Obesity-drug combination results

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. TD Cowen restated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a report on Thursday, September 17th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,211.08 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50 day moving average price of $1,177.42 and a two-hundred day moving average price of $1,104.28. The firm has a market capitalization of $1.14 trillion, a P/E ratio of 40.64, a P/E/G ratio of 1.50 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 34.79 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.